evipedia.ai
← Back

Psilocybin for Health & Longevity

Evidence Review created on 08/21/2026 using AI4L / Opus 5

Also known as: Psilocybine, 4-phosphoryloxy-N,N-dimethyltryptamine, O-phosphoryl-4-hydroxy-N,N-dimethyltryptamine, Magic Mushrooms, COMP360, PEX010

Motivation

Psilocybin is the psychoactive compound produced by roughly two hundred species of mushroom, most of them in the genus Psilocybe. Once swallowed it is converted in the body to psilocin, which acts on serotonin receptors and temporarily changes how brain regions communicate with one another. Interest has grown because a single supervised dose appears to shift mood and behavior for weeks or months rather than for hours.

Mushrooms containing it were used in Mesoamerican ceremony long before Western chemists isolated the compound in the late 1950s. Laboratory and clinical work stalled for decades after the substance was outlawed, then restarted around the turn of the century. More recently, findings in cultured cells and in old mice raised a newer and separate question: whether the compound touches the biology of aging itself, outside the brain.

This review examines what is known about psilocybin in relation to health and longevity — the mechanisms proposed for it, the outcomes measured in controlled human trials, the harms recorded alongside those outcomes, the protocols used by the groups running the trials, and the distance between the aging findings and any claim about people.

Benefits - Risks - Protocol - Conclusion

High-level overviews of psilocybin from expert practitioners and longevity-focused publications, selected for depth rather than novelty.

Relevant psilocybin content also exists on lifeextension.com, within its anxiety protocol, but it is not listed because the section is limited to five items and the five above are more directly focused on the compound itself.

Grokipedia

  • Psilocybin

    Broad reference entry spanning chemistry, natural sources, pharmacology, effects, and safety, useful as an orientation layer before reading the primary trial literature covered below.

Examine

  • Psilocybin

    Examine’s dedicated intervention page, graded from its own database. Notably thin — it credits only 132 trial participants and one meta-analysis, and covers cognitive improvement as the sole outcome.

ConsumerLab

No ConsumerLab article on psilocybin exists. ConsumerLab tests supplements and related products sold at retail; psilocybin is a controlled substance that cannot be sold as a supplement in the markets ConsumerLab covers, and is available only through clinical trials, state-licensed service programs, or prescription in Australia, so it falls outside the scope of its testing programs.

Systematic Reviews

Pooled analyses of psilocybin trials, selected to cover both the claimed benefits and the principal harms.

Mechanism of Action

Psilocybin is a prodrug. Alkaline phosphatase in the gut wall and blood strips off its phosphate group within minutes, releasing psilocin, the active molecule. Psilocin partially activates several serotonin receptors, but the psychedelic effect depends specifically on the 5-HT2A receptor (a docking site for the brain chemical serotonin) — blocking that receptor with ketanserin abolishes the experience entirely.

Activating 5-HT2A receptors on deep-layer cortical neurons increases glutamate signaling and desynchronizes the default mode network (the brain network that runs during self-referential thought), loosening habitual patterns of self-modeling. In rodents this is followed within a day by measurable dendritic spine growth in the frontal cortex, and that structural change is the leading account of why one dose can produce effects lasting weeks.

A competing account holds that receptor activation matters mainly because it generates an intense, personally meaningful subjective experience, and that the experience rather than the synapse carries the effect. Non-hallucinogenic 5-HT2A agonists are in development to separate the two.

5-HT2A receptors also sit on fibroblasts, immune cells, and blood-vessel lining, which grounds the newer proposal that psilocin acts systemically by raising sirtuin 1 and antioxidant defenses.

Pharmacologically, oral bioavailability is about 53%, psilocin peaks at roughly two hours, and the elimination half-life is 1.5–4 hours. Clearance is by glucuronidation through UGT1A10 (an enzyme that tags drugs for excretion), with contributions from CYP2D6 and CYP3A4 (liver enzymes that break down drugs) and monoamine oxidase A (an enzyme that degrades serotonin-like molecules).

Historical Context & Evolution

Psilocybin’s original use was not medical in the modern sense. Mushrooms containing it appear in Mesoamerican ritual under the Nahuatl name teonanácatl, recorded by Spanish chroniclers in the sixteenth century. R. Gordon Wasson’s 1957 account of a Mazatec ceremony brought them to Western attention, and Albert Hofmann isolated and synthesized psilocybin at Sandoz in 1958. Sandoz then marketed it as Indocybin for psycholytic psychotherapy (repeated modest doses used to loosen defences during talk therapy), and several thousand participants received psilocybin or related compounds before 1970.

Two strands of that early work are usually named. Timothy Leary’s Harvard Psilocybin Project produced the Concord Prison recidivism study and the Good Friday Experiment; a larger, quieter European psycholytic literature ran in parallel. The Concord study’s original claim of reduced reoffending did not hold up: Rick Doblin’s 1998 long-term follow-up recalculated recidivism against proper base rates and found no advantage. The Good Friday Experiment’s core finding — that psilocybin reliably occasions experiences participants rate as among the most spiritually significant of their lives — has since been replicated under modern controls, though Doblin’s follow-up of that experiment documented an adverse reaction the original report omitted.

Scheduling under the 1970 US Controlled Substances Act and the 1971 UN convention halted the field for three decades. It resumed with Roland Griffiths’s 2006 healthy-volunteer study. The pivot toward health optimization has a simple driver: durability of effect after a single exposure is unusual among psychiatric interventions, and durability is what a longevity-oriented reader wants.

Expected Benefits

High 🟩 🟩 🟩

Rapid and Durable Reduction of Depressive Symptoms ⚠️ Conflicted

A single 25 mg dose with psychological support lowers clinician-rated depression scores within days, and the separation persists at three to six weeks. Evidence spans nine randomized trials pooled in meta-analysis, a placebo-controlled trial in major depressive disorder, and a dose-ranging trial in treatment-resistant depression run and funded by the patent holder, COMPASS Pathways. The conflict is how much of the effect is drug: blinding fails, and an incremental-efficacy analysis found the advantage over placebo modest once expectancy is accounted for.

Magnitude: Hedges’ g (a standardized effect size) = 0.66 (95% confidence interval — the range within which the true effect most likely falls — 0.46 to 0.86) across seven trials and 436 participants; individual trials reported clinician-rated MADRS (Montgomery-Åsberg Depression Rating Scale, a 0-to-60 depression score) differences of 6.6 to 12.3 points versus comparator.

Medium 🟩 🟩

Reduced Heavy Drinking in Alcohol Use Disorder

Two supervised doses alongside twelve weeks of manualized psychotherapy roughly halved heavy drinking days over eight months compared with an active placebo in a double-blind randomized trial. The proposed mechanism is a durable shift in the salience of drinking cues and in self-efficacy, not a direct pharmacological effect on craving. Support includes an open-label single-dose study and a systematic review with meta-analysis of psychedelic trials in this indication, which is dominated by older lysergic acid diethylamide studies rather than psilocybin and rates most of them at high risk of bias.

Magnitude: Heavy drinking days 9.7% versus 23.6% over the 32-week double-blind period, a difference of 13.9 percentage points (95% confidence interval 3.0 to 24.7).

Sustained Tobacco Smoking Abstinence

One high dose given on the target quit date alongside thirteen weeks of cognitive behavioral therapy (a structured talking therapy targeting thoughts and habits) produced abstinence rates several times those of the nicotine patch at six months in a pilot randomized trial. The trial was unblinded by design, the participants were psychiatrically healthy volunteers who had sought out a psychedelic study, and the sample was small — all of which inflate the apparent effect. It remains the only randomized comparison against an approved cessation aid.

Magnitude: 40.5% versus 10.0% biochemically verified prolonged abstinence at six months (odds ratio — the ratio of the odds of an outcome between two groups — 6.12, 95% confidence interval 1.99 to 23.26).

Reduced Cocaine Use in Cocaine Use Disorder

One supervised dose alongside manualized psychotherapy raised the share of cocaine-free days and cut relapse risk through six months against an active placebo in a quadruple-blind randomized trial. The proposed mechanism mirrors the alcohol and tobacco findings: a shift in motivation and self-efficacy rather than a direct pharmacological effect on craving. The trial is small, single-site, and so far unreplicated, and no pooled analysis exists; its weight comes from the absence of any medication proven effective for this condition.

Magnitude: 28.95 percentage points more cocaine-abstinent days than active placebo (95% confidence interval 18.22 to 39.67), with an odds ratio of 18.37 for complete abstinence through 180 days after treatment.

Relief of Anxiety and Existential Distress in Life-Threatening Illness

In people facing cancer or another life-limiting diagnosis, one or two supervised doses reduce anxiety, depression, and demoralization; a randomized crossover trial in advanced cancer found 60–80% of participants still had clinically significant reductions at 6.5 months. The Cochrane review pooling six randomized trials rated this low-certainty: samples are small, blinding fails, and the trials were funded by organizations existing to advance psychedelic therapy.

Magnitude: Trait anxiety 8.4 points lower than active placebo on a 20-to-80 scale (95% confidence interval 3.9 to 12.9); depression 4.9 points lower on a 0-to-63 scale.

Low 🟩

Durable Gains in Well-Being and Trait Openness in Healthy Adults

Healthy volunteers given a high dose in a supportive setting report sustained increases in life satisfaction and personal meaning and in the personality trait of openness. The evidence is open-label, self-reported, and drawn from self-selected volunteers, so expectancy is entirely uncontrolled.

Magnitude: At 14 months, 58% of volunteers rated the session among the five most personally meaningful experiences of their lives; openness gains persisted beyond a year, but only in those who had a complete mystical-type experience.

Reduction in Cluster Headache Burden

A low-dose three-pulse regimen reduced attack frequency in an exploratory randomized trial. The primary comparison was not statistically significant, but the effect was large in the chronic subgroup and unrelated to how intense the psychedelic effects were, which argues for a non-psychological mechanism.

Magnitude: −3.2 attacks per week versus +0.03 with placebo over three weeks (between-group effect size 0.69 overall, 1.25 in chronic cluster headache); the primary comparison gave p = 0.251 (a p-value, the probability of seeing a difference this large if the drug did nothing; values above 0.05 are conventionally read as inconclusive) in fourteen analyzed participants.

Reduction in Obsessive-Compulsive Symptoms

Repeated weekly doses lowered Yale-Brown obsessive-compulsive scale scores in a small randomized phase 1 trial that used an active placebo, and a 10 mg challenge study reproduced the effect for roughly a week. Both samples were tiny; the first trial was double-blind only initially and the second was non-randomized.

Magnitude: 73.3% of participants were responders (a reduction of at least 35% in symptom score) with 40% in remission after four or more high doses, while active placebo produced no significant symptom reduction; the single-dose study gave a between-dose effect size of 0.82 at one week.

Speculative 🟨

Geroprotective Effects on Cellular Senescence and Survival

Psilocin extended replicative lifespan and preserved telomere length in human fibroblasts, and monthly psilocybin improved ten-month survival in aged mice. The basis is a single preclinical report; no human aging outcome has been measured.

Systemic Anti-Inflammatory Effects

Serotonin 2A receptors on immune cells may dampen inflammatory signaling. An open-label study in healthy humans found no clear change in inflammatory markers after one dose, so the basis remains preclinical and mechanistic.

Neuroplastic Support for the Aging Brain

Rodent work shows frontal dendritic spine growth within a day of dosing, which could in principle offset age-related synaptic loss. No trial in cognitively healthy older adults has reported outcomes.

Benefit-Modifying Factors

  • Prior psychedelic experience: The strongest single moderator identified in meta-analysis. Prior users show substantially larger measured improvements, which plausibly reflects expectancy and reduced acute anxiety rather than a pharmacological difference.
  • Set, setting, and preparatory support: Quality of preparation, the physical environment, and the presence of trained monitors shape the acute experience, and the intensity of that experience predicts outcome in most trials of depression and addiction.
  • CYP2D6 metabolizer status: CYP2D6 is a liver enzyme that helps clear psilocin. Poor metabolizers reach higher psilocin exposure from a fixed dose, which may increase both effect intensity and side-effect burden; no dosing algorithm exists.
  • HTR2A receptor variation: HTR2A encodes the 5-HT2A receptor. Common variants alter receptor density and signaling and are associated with antidepressant response generally, but no variant has been validated as predicting psilocybin response.
  • Baseline biomarker levels: Higher baseline depression severity predicts larger absolute improvement, partly through regression to the mean (extreme starting scores tend to drift toward average on retesting). Baseline 5-HT2A receptor binding measured by brain imaging predicts the intensity of the subjective experience.
  • Sex-based differences: Fixed dosing produces comparable psilocin exposure in men and women, and no consistent sex difference in efficacy has emerged from trials. The mouse geroprotection work used females only, so its sex-generality is untested.
  • Pre-existing health conditions: Depression secondary to another condition, such as cancer, showed larger pooled effects than primary depression. Chronic serotonergic antidepressant use is widely reported to blunt the acute experience, though controlled data in healthy volunteers do not confirm it.
  • Age: Trial populations center on ages 30 to 60. Older adults are underrepresented, and while the mouse work began treatment at an age equivalent to 60–65 human years, no efficacy or aging outcome has been measured in older people.

Potential Risks & Side Effects

High 🟥 🟥 🟥

Nausea and Vomiting

Nausea is the single most reliable acute effect of a therapeutic dose, beginning in the first hour as psilocin acts on serotonin receptors in the gut and the brainstem vomiting center. It is transient, resolves as blood levels fall, and is routinely pre-empted with an antiemetic (an anti-nausea medication) in trial settings. Across pooled double-blind trials it carries the largest relative excess over control of any adverse effect.

Magnitude: Relative risk (how many times more likely an event is than in the comparison group) 8.85 (95% confidence interval 5.68 to 13.79) across six double-blind trials.

Headache and Dizziness

Headache typically starts as the acute effects fade and can peak the following day; the leading explanation is transient serotonin-mediated narrowing of blood vessels followed by rebound widening. Dizziness occurs around the drug’s peak. Both are mild to moderate, self-limiting within 24 to 48 hours, and respond to ordinary painkillers. Headache was reported across all dose arms of the treatment-resistant depression trial, including the 1 mg comparator.

Magnitude: Headache relative risk 1.99 (95% confidence interval 1.06 to 3.74); dizziness relative risk 5.81 (95% confidence interval 1.02 to 33.03).

Acute Anxiety and Challenging Experience

Intense fear, paranoia, or a sense of dying occurs in a meaningful minority of sessions and is the reason trials require two trained monitors present for the full six to eight hours. The mechanism is the same receptor action that produces the therapeutic effect, so the two cannot be separated pharmacologically. Severity tracks dose, prior experience, expectation, and setting, and in supervised settings it is usually managed by reassurance rather than medication. A safety-focused meta-analysis of six double-blind trials found treatment-emergent anxiety significantly more frequent on psilocybin than control.

Magnitude: Relative risk 2.27 (95% confidence interval 1.11 to 4.64) for treatment-emergent anxiety versus control.

Transient Rise in Blood Pressure and Heart Rate

Psilocin raises blood pressure and heart rate for roughly two to four hours through peripheral serotonin receptor activation, peaking with the subjective effects. In screened trial participants this is clinically unimportant, which is precisely why trials exclude uncontrolled hypertension and unstable cardiac disease. Elevated blood pressure was one of the effects significantly more common on psilocybin in a pooled safety analysis. A case report of psilocybin-induced fainting shows the response is not always upward.

Magnitude: Elevated blood pressure relative risk 2.29 (95% confidence interval 1.15 to 4.53) versus control; pooled trials report no sustained change beyond the session.

Medium 🟥 🟥

Symptom Worsening and Suicidal Ideation ⚠️ Conflicted

A minority of participants leave these trials worse than they arrived. In the phase 2 treatment-resistant depression trial, suicidal ideation, suicidal behavior, or self-injury was recorded in every dose arm including the 1 mg comparator. The conflict is directional: pooled individual-participant data put clinically significant worsening at roughly one in ten, no worse than escitalopram and far better than a waiting list, while serious adverse events do occur in psychiatric populations.

Magnitude: About 10% of participants showed clinically significant worsening versus 63.6% on a waiting list; serious adverse events occurred in roughly 4% of participants with pre-existing neuropsychiatric disorders across 114 analyzable studies, and in none of the healthy participants.

Precipitation of Mania, Hypomania, or Psychosis

Serotonin 2A activation can tip people with bipolar-spectrum or psychosis vulnerability into mania or a psychotic episode. Reported rates rise steeply from screened trial populations to unscreened naturalistic use in people who already have bipolar disorder, according to a systematic review and meta-analysis. Episodes are usually acute and self-limited, but this is the basis for the standard exclusion of personal or first-degree family history of bipolar I disorder or schizophrenia.

Magnitude: 5.8% in controlled psilocybin trials for depression versus up to 30% in naturalistic samples of people with bipolar disorder; registry cohorts show 4% (95% confidence interval 2% to 8%) subsequently receiving a bipolar diagnosis, with no psychedelic-specific signal.

Low 🟥

Hallucinogen Persisting Perception Disorder

Lingering visual disturbances — trails, halos, visual static — persisting for months after exposure. A scoping review of the case literature links it mainly to repeated unsupervised use of assorted hallucinogens; no case has been reported in a contemporary supervised psilocybin trial.

Magnitude: Not quantified in available studies. No controlled trial has measured its incidence, and the published literature consists of case reports and clinic series with no denominator from which a rate could be derived.

Transient Cognitive and Functional Impairment

Attention, working memory, and cognitive flexibility are impaired for the duration of the acute effects, making driving and consequential decisions unsafe that day. A systematic review of twenty studies found global cognition and processing speed largely unchanged once the acute window closes.

Magnitude: Impairment is confined to the four-to-eight-hour acute window and reverses fully; the cognition review reports no pooled figure because the included studies used incompatible test batteries.

Speculative 🟨

Cardiac Valvulopathy (Damage to a Heart Valve) with Repeated Low-Dose Exposure

Psilocin binds the serotonin 2B receptor, the target implicated in fenfluramine and ergot valve disease. No valve injury has been reported with psilocybin; the concern is purely mechanistic and applies to sustained daily microdosing.

Adverse Effects in the Postpartum Period

In mice, psilocybin given to mothers after birth raised anxiety weeks later and produced anhedonia (loss of pleasure) in nursing offspring. No human data exist; the basis is a single preclinical study.

Tumor-Promoting Potential of Delayed Senescence

Delaying replicative senescence is the proposed geroprotective mechanism, and the same delay could in principle favor tumor growth. The authors of the mouse work flag this explicitly; no cancer outcome data exist.

Risk-Modifying Factors

  • Family history of bipolar or psychotic illness: The strongest known risk modifier. First-degree relatives carry substantial heritable liability, and naturalistic use in this group is where mania and psychosis reports concentrate.
  • CYP2D6 poor-metabolizer status: Reduced activity of this drug-clearing liver enzyme raises psilocin exposure from a fixed dose, plausibly increasing nausea, anxiety, and cardiovascular response.
  • Baseline blood pressure and cardiac electrical recovery: Resting blood pressure above 140/90 mmHg or a prolonged corrected QT interval (the heart’s electrical recovery time) on electrocardiogram converts a routine transient rise into a meaningful cardiac risk.
  • Pre-existing health conditions: Uncontrolled hypertension, unstable coronary disease, existing valve regurgitation, epilepsy, and significant liver impairment all raise risk. Personality disorders with instability raise the risk of a distressing session.
  • Sex-based differences: No consistent sex difference in adverse-event rates has emerged from trials. The one clear sex-specific signal is preclinical and concerns the postpartum period, where treated mouse mothers and their nursing offspring were harmed.
  • Age: Older adults have higher background rates of hypertension, valve disease, and polypharmacy, which magnifies the cardiovascular and interaction risks rather than the psychological ones. Dedicated safety trials in people over 65 are only now recruiting.

Key Interactions & Contraindications

  • Monoamine oxidase inhibitors (phenelzine, tranylcypromine, moclobemide): Absolute contraindication. These block a major psilocin clearance route, markedly prolonging and intensifying effects and risking serotonin toxicity. Mitigation: two-week washout, six weeks for irreversible agents, under prescriber supervision.
  • Lithium: Absolute contraindication. Case series report seizures and severe adverse reactions when psychedelics are taken on lithium, a combination not present in any modern trial. Mitigation: no co-administration, with any change to lithium therapy made only under psychiatric supervision.
  • Selective serotonin reuptake inhibitors and serotonin-norepinephrine reuptake inhibitors (escitalopram, sertraline, venlafaxine): Caution, efficacy consequence rather than safety. A crossover study of escitalopram pretreatment cut adverse effects without cutting positive mood effects. Mitigation: supervised taper two weeks before dosing, six for fluoxetine.
  • Tricyclic antidepressants (amitriptyline, imipramine): Caution. Tricyclics amplify psychedelic effects and add anticholinergic (dry mouth, constipation, blurred vision) and cardiac load, per a systematic review of psychiatric drug interactions. Mitigation: tapered under supervision.
  • Antipsychotics (risperidone, olanzapine, quetiapine): Caution. As 5-HT2A blockers they blunt or abolish the experience, wasting the exposure. Mitigation: not co-administered; low-dose risperidone is instead held as rescue medication for a session that cannot be settled otherwise.
  • Over-the-counter serotonergic medicines (dextromethorphan cough preparations, high-dose diphenhydramine): Caution. Dextromethorphan adds serotonergic and dissociative load with unpredictable results. Mitigation: cough and cold preparations are stopped 48 hours before dosing.
  • Serotonergic supplements with additive effects (St John’s wort — Hypericum perforatum, 5-hydroxytryptophan, L-tryptophan, S-adenosylmethionine): Caution. These raise serotonin availability on top of direct receptor activation. Mitigation: discontinued two weeks before dosing.
  • Monoamine-oxidase-inhibiting botanicals (Syrian rue — Peganum harmala, harmala alkaloids): Caution to avoid. These reproduce the pharmacology of prescription monoamine oxidase inhibitors, greatly prolonging effects. Mitigation: no co-administration, including in “enhanced” mushroom products.
  • Stimulants (amphetamine, methylphenidate, high-dose caffeine): Caution. Additive rise in blood pressure and heart rate plus increased anxiety. Mitigation: omitted on the dosing day and the day before.
  • Other interventions (cannabis, alcohol, other psychedelics): Caution. Cannabis reliably amplifies acute anxiety; other psychedelics share cross-tolerance for several days. Mitigation: cannabis and alcohol avoided for at least 24 hours before and after.

Populations who should avoid Psilocybin:

  • Personal or first-degree family history of schizophrenia, schizoaffective disorder, or bipolar I disorder
  • Uncontrolled hypertension, defined as resting blood pressure at or above 140/90 mmHg despite treatment
  • Unstable cardiovascular disease: myocardial infarction within 6 months, unstable angina, NYHA (New York Heart Association) Class III–IV heart failure, or moderate-or-greater valvular regurgitation
  • Corrected QT interval above 450 ms in men or 470 ms in women on baseline electrocardiogram
  • Seizure disorder, or current lithium therapy
  • Child-Pugh Class B or C liver impairment (a severity grading of chronic liver disease), given hepatic clearance of psilocin
  • Pregnancy and breastfeeding
  • Active suicidal ideation with intent or plan

Risk Mitigation Strategies

  • Structured psychiatric screening: A formal interview covering personal and first-degree family history of bipolar I disorder and psychotic illness, which is the single highest-yield step for preventing mania and psychotic decompensation.
  • Cardiac screening before first exposure: Resting blood pressure below 140/90 mmHg on two readings plus a baseline twelve-lead electrocardiogram, to exclude the arrhythmia and hypertensive-crisis risk from the transient cardiovascular rise.
  • Supervised antidepressant taper: Serotonergic antidepressants stopped two weeks before dosing, six weeks for fluoxetine, under prescriber supervision — preventing both blunted response and discontinuation symptoms mistaken for drug effects.
  • Two trained monitors for the full session: Continuous presence of two people for six to eight hours, the trial standard, which converts acute anxiety and paranoia from a crisis into a managed event resolved by reassurance.
  • Dose escalation across sessions: Protocols start at 10 mg and move to 25 mg only after a tolerated first session, reducing the probability of an overwhelming challenging experience at first exposure.
  • Pre-dose antiemetic and overnight fast: Ondansetron 4–8 mg 30 minutes before dosing with an overnight fast and a light low-fat breakfast, targeting the near-universal nausea.
  • Rescue medication on hand: Lorazepam 1–2 mg for unmanageable anxiety and low-dose risperidone for persistent psychotic features, available but used only after non-drug reassurance fails.
  • In-session vital sign monitoring: Blood pressure and pulse before dosing and at 30, 60, 90, and 120 minutes, catching hypertensive excursions and the rarer fainting response early.
  • No driving or consequential decisions for 24 hours: A firm same-day and next-morning restriction, addressing the transient impairment of attention, working memory, and judgment.
  • Scheduled integration sessions: At least two structured follow-up conversations within two weeks, which is where symptom worsening and emerging suicidal ideation are most likely to be detected and acted on.

Therapeutic Protocol

  • Standard supported-session model: One 25 mg oral dose of synthetic psilocybin in a living-room-style room, eyeshades and curated music, two monitors present for six to eight hours. Popularized by Roland Griffiths and Matthew Johnson at Johns Hopkins.
  • Two-dose model: Two sessions three to five weeks apart, 25 mg then 25–40 mg per 70 kg, embedded in twelve weeks of psychotherapy. Developed by Michael Bogenschutz and Stephen Ross at NYU for addiction.
  • Non-medical facilitated model: Oregon’s licensed service centers deliver supervised sessions without a diagnosis or prescriber, using trained facilitators rather than clinicians. Colorado’s healing centers follow a similar design.
  • Low-dose pulse regimen: Three doses of roughly 0.14 mg/kg spaced five days apart, developed by Emmanuelle Schindler at Yale specifically for cluster headache rather than mood.
  • Microdosing: Roughly 1–3 mg every third day. Widely practiced but not supported: pooled randomized data show no separation from placebo on mood, anxiety, or stress in healthy adults.
  • Time of day: Dosing between 9:00 and 10:00 in the morning is standard, so acute effects resolve by early evening and the participant is not left unsupervised or unable to sleep.
  • Half-life and duration: Psilocin peaks at about two hours with an elimination half-life of 1.5–4 hours. Onset is 20–40 minutes and subjective effects last 5.5 to 6.5 hours dose-dependently.
  • Single versus split dosing: A single dose is the trial standard. Supplemental mid-session doses are not used, because the second peak extends the session past the monitoring window without evidence of added benefit.
  • Fixed rather than weight-adjusted dosing: Body weight did not influence psilocin exposure or response across 79 healthy participants, so fixed milligram dosing has largely replaced the older per-kilogram convention.
  • Genetic polymorphisms: CYP2D6 poor metabolizers reach higher psilocin exposure and may warrant starting at 10 mg. COMT and MTHFR variants, which affect neurotransmitter breakdown and folate processing, have no validated role in psilocybin dosing.
  • Sex-based differences: No dose adjustment by sex is used in any trial protocol, and fixed dosing produces comparable exposure. The evidence base for sex-specific response remains thin and inconsistent.
  • Age-related considerations: Trials cap enrollment around 65. For older participants, protocols emphasize cardiac screening and medication review rather than dose reduction; dedicated tolerability studies in 65-to-85-year-olds are only now recruiting.
  • Baseline biomarkers and conditions: Higher baseline symptom severity predicts larger absolute change. Controlled blood pressure, intact liver function, and absence of the excluded psychiatric histories are the practical gatekeepers for proceeding.

Discontinuation & Cycling

  • Episodic, not lifelong: Psilocybin is given as one or two discrete exposures, not as continuing therapy. There is no maintenance regimen in any trial protocol, and effects are tracked as they decay rather than sustained by redosing.
  • No withdrawal syndrome: Psilocybin produces no physical dependence and no withdrawal state. Abuse-potential assessments place it well below scheduled stimulants and opioids; there is nothing to discontinue from pharmacologically.
  • Tapering not applicable: Because exposure is discrete rather than continuous, no taper exists. The taper that matters runs the other way — off serotonergic antidepressants before dosing, and the decision about restarting them afterwards.
  • Acute tolerance limits close repeat dosing: 5-HT2A receptors downregulate rapidly, and a second dose within a few days produces markedly reduced effects. Trials therefore space repeat sessions three to five weeks apart.
  • Cycling is not established: No evidence supports scheduled cycling to maintain efficacy. Where effects fade, trials have tested a single repeat dose rather than a cycle, and durability beyond six months after one exposure remains poorly characterized.

Sourcing and Quality

  • Pharmaceutical-grade synthetic material: Trials use defined synthetic preparations — COMP360, Usona’s psilocybin, and Filament’s PEX010 — with assayed potency. These are the only forms with documented purity and are available only inside trials or licensed programs.
  • Alkaloid variability in mushrooms: Psilocybin content in dried Psilocybe cubensis ranges roughly 0.5–2% by weight and varies between caps, stems, and flushes, so a gram measurement translates poorly into a milligram dose.
  • Accompanying alkaloids: Mushrooms also contain baeocystin, norbaeocystin, and aeruginascin, whose contributions are uncharacterized. A synthetic single-molecule product removes this variable; a whole-mushroom product does not.
  • What to look for in regulated channels: Oregon and Colorado programs require batch testing by licensed laboratories for potency, pesticides, heavy metals, and microbial contamination, with results tied to a batch identifier, and the certificate is available on request.
  • Misidentification risk: Foraged material risks confusion with Galerina marginata, which contains lethal amatoxins and resembles small brown Psilocybe species. Species identification is the single largest avoidable hazard in unregulated sourcing.
  • Counterfeit and adulterated products: Products marketed as psilocybin frequently contain 4-acetoxy-N,N-dimethyltryptamine or unrelated research chemicals. Independent testing has also found psilocybin as an undeclared contaminant in retail hemp-derived products.

Practical Considerations

  • Time to effect: Acute effects begin 20–40 minutes after dosing. Depression scores drop measurably by day two, with the largest separation from control at weeks two to three, and durability measured in weeks to months rather than days.
  • Common pitfalls: Dosing without preparation or integration, an unsafe setting, failing to taper serotonergic antidepressants first, and substituting microdosing for a full supervised session in the belief that it delivers the same benefit.
  • Regulatory status: Schedule I federally in the United States and unapproved by the FDA (Food and Drug Administration, the US medicines regulator) as of August 2026. Supervised access exists through Oregon, Colorado, and New Mexico programs, and by Authorised Prescriber in Australia.
  • Cost and accessibility: A supervised session in a licensed Oregon center typically runs US$1,000–3,500 out of pocket, uninsured, plus preparation and integration hours and a full day off.
  • Who funds the evidence: Most trials are financed by companies holding formulation patents, by non-profits founded to advance the compound, or by advocacy organizations — a structural bias toward publishing favorable results.
  • The opposing payer incentive: Insurers and national health systems face the reverse pressure, since generic antidepressants cost a few dollars monthly against thousands per supervised session, which shapes reimbursement decisions and guideline formation independently of the evidence.

Interaction with Foundational Habits

  • Sleep: Direct and biphasic. Sessions start in the morning because acute effects suppress and fragment sleep that night, with reduced dreaming sleep reported after dosing. Within weeks, trials report sleep quality improving alongside mood. Practical point: the dosing night is left unscheduled and sedatives are not used to force sleep.
  • Nutrition: Indirect. An overnight fast followed by a light low-fat breakfast is the trial standard and reduces nausea without meaningfully changing absorption. Serotonergic supplements — St John’s wort, 5-hydroxytryptophan, tryptophan loading — are held for two weeks beforehand. Grapefruit juice inhibits enzymes that clear psilocin and is avoided.
  • Exercise: Essentially none pharmacologically. There is no evidence that psilocybin blunts training adaptation or hypertrophy, and none that it enhances performance. Practical points: hard training is avoided on the dosing day, since blood pressure and heart rate are already elevated, and resumed normally the next day.
  • Stress management: Potentiating and bidirectional. Psilocybin appears to work partly by loosening rigid self-referential thought, the same target as meditation, and a randomized trial dosing during a five-day mindfulness retreat produced larger gains in psychosocial functioning at four months than the retreat with placebo. Conversely, high ambient stress makes a difficult session more likely.

Monitoring Protocol & Defining Success

Baseline work is done in the two to four weeks before a session and serves two purposes: screening out the exclusions listed above, and establishing personal reference points against which any later change can be read. That means a seated blood pressure reading after five minutes of rest, a twelve-lead electrocardiogram, a liver panel, a fasting inflammatory marker, and scored symptom questionnaires completed before rather than after the decision to proceed. During the session, blood pressure and pulse are taken before dosing and at 30, 60, 90, and 120 minutes. Afterwards, symptom scales are repeated at day 2, day 8, week 3, and week 6, then every 3 months through the first year. Anyone repeating exposure rechecks blood pressure, liver enzymes, and inflammatory markers annually, adding an echocardiogram only where low-dose exposure has been frequent and sustained.

Biomarker Optimal Functional Range Why Measure It? Context/Notes
Resting blood pressure Below 120/80 mmHg Psilocybin transiently raises it; a high starting point makes the rise consequential Seated, after 5 minutes of rest, averaged over two readings. Conventional hypertension thresholds start at 130/80 mmHg, so a “normal” clinic reading can still sit above the functional target
Corrected QT interval (QTc) Below 440 ms (men), below 460 ms (women) Screens for the arrhythmia vulnerability that turns a sympathetic surge into a cardiac event QTc is the heart’s electrical recovery time adjusted for rate, read from a twelve-lead electrocardiogram. Conventional cut-offs are more permissive at 450/470 ms
hs-CRP Below 1.0 mg/L Tracks the systemic inflammation that psilocybin has been proposed but not shown to lower hs-CRP is high-sensitivity C-reactive protein, a general marker of body-wide inflammation. Fasting draw; defer 2 weeks after any infection or intense training block. Conventional labs call anything under 3.0 mg/L normal
ALT Below 25 U/L (men), below 20 U/L (women) Psilocin is cleared by the liver, so impaired function raises exposure from a fixed dose ALT is alanine aminotransferase, an enzyme that leaks from liver cells when they are stressed. Fasting morning draw, paired with AST (aspartate aminotransferase) and GGT (gamma-glutamyl transferase), two further liver enzymes. Conventional upper limits run to 40–55 U/L
eGFR Above 90 mL/min/1.73 m² Psilocin metabolites are renally excreted; reduced clearance prolongs exposure eGFR is estimated glomerular filtration rate, a calculated measure of kidney filtering capacity. Best paired with cystatin C in lean or highly muscular people, where creatinine alone misleads
PHQ-9 score 4 or below The primary success criterion where depressive symptoms were the reason for dosing PHQ-9 is the nine-item Patient Health Questionnaire, a self-report depression scale. Self-report scales showed larger psilocybin effects than clinician ratings, so measured improvements read as generous
GAD-7 score 4 or below Captures the anxiety component, which often moves independently of mood GAD-7 is the seven-item Generalized Anxiety Disorder scale. Completed before rather than after learning what was taken, to limit expectancy contamination
Trait openness No established target; track the change from the individual’s own pre-session score The most reproducible personality change reported after high-dose exposure Measured with the NEO Personality Inventory, a standard five-factor personality questionnaire. Change is read against the individual’s own pre-session baseline, since there is no population target and absolute scores are meaningless here
Epigenetic age No established target; track the change from the individual’s own baseline using one provider The only human-measurable proxy for the geroprotection hypothesis DNA methylation clocks are not standardized between laboratories. Change is read against the individual’s own baseline using a single provider, and any single reading is noise

Qualitative markers matter at least as much as the panel, because the outcomes psilocybin is claimed to move are largely subjective. Worth tracking:

  • Sleep quality and how rested mornings feel, week by week
  • Energy and drive through the afternoon, distinct from mood
  • Emotional reactivity — how quickly small setbacks escalate
  • Cognitive clarity and the ease of switching between tasks
  • Sense of meaning, connection, and engagement with people and work
  • Cravings for alcohol or nicotine, where those were the target
  • Any lingering visual disturbances, however mild

Emerging Research

  • Second phase 3 trial in treatment-resistant depression: NCT05711940, 572 participants, comparing two 25 mg administrations against 1 mg on depression score change. Longer-term data through week 26 are the point of interest, since durability is the open question.
  • Independent phase 3 in major depressive disorder: NCT06308653, 238 participants, run by the non-profit Usona Institute. A second sponsor reaching phase 3 tests whether the effect replicates outside the patent holder’s program.
  • Psilocybin and biomarkers of aging: NCT07719088, a 50-participant phase 1 study explicitly registered under aging, longevity, and biomarkers of aging. The first attempt to test the geroprotection claim in people rather than mice.
  • Neuroplasticity in aging and Alzheimer’s disease: NCT07721467, a 200-participant phase 2 trial funded by the National Institute on Aging, pairing psilocybin with cognitive training against a neuroplasticity composite score.
  • Healthy older adults, safety and brain structure: NCT07516405, a phase 1 safety and tolerability trial in ages 65–85, and NCT06367738, a dose-ranging imaging study of structural plasticity in ages 60–85. Each enrols 40 participants beyond typical trial caps.
  • Evidence that could weaken the antidepressant case: Hieronymus et al., 2025 compared control-group outcomes across psilocybin, antidepressant, and esketamine trials, probing whether unusually poor comparator performance rather than drug effect drives the observed separation.
  • Evidence that could weaken the durability case: Goodwin et al., 2025 followed treatment-resistant depression participants long-term after a single dose, testing how much of the initial response survives without redosing.
  • Direct challenge to the human longevity inference: Lerer, 2026 compared mortality among prominent psychedelic users against cancer and aging researchers and found no survival advantage, arguing the mouse result cannot yet be extrapolated.
  • Methodological moderators under scrutiny: Syed et al., 2026 examines how much of the pooled antidepressant effect is attributable to trial design choices — comparator type, therapy quantity, and blinding integrity — rather than the compound.

Conclusion

Psilocybin is a mushroom compound that, in a single supervised dose, produces several hours of altered perception and thought and, in a substantial fraction of people, a shift in mood and behavior lasting weeks or months after the drug has cleared. The strongest evidence concerns depressive symptoms, where controlled trials repeatedly separate it from dummy treatments. Support is thinner but real for heavy drinking, tobacco and cocaine use, and the distress of serious illness. The most common harms — nausea, headache, brief anxiety, and a short-lived rise in blood pressure — resolve within a day or two. The harms that matter more are rarer and harder to count: worsening mood in a minority, and mood or thought disturbance in people carrying a family vulnerability to it.

The evidence carries two structural weaknesses. Almost nobody stays blinded in these trials, which inflates apparent benefit by an unknown amount. And much of the work is funded by companies holding patents on the formulations, by non-profits founded to advance the compound, and by advocacy groups — while insurers and national health systems face the opposite pull, since the established alternatives cost a few dollars a month against thousands for one supervised session.

The claim that psilocybin slows biological aging rests on cultured cells and one study in old mice. Nothing in people tests it, and the one published attempt to find a longevity signal among heavy psychedelic users found none.

Top - Benefits - Risks - Protocol